Komori
Kringle Pharma (4884) · RiskMitigated

Share price declines resulting from venture capital and other investors selling shares

First written in FY2020. 3 of 4 entries say "Mitigated", first in FY2022. Latest entry: FY2024.

4entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2020MitigatedFY2022 – FY20242020: 12021: 020212022: 120222023: 120232024: 12024
Same theme, other companies
Deterioration in Supply and Demand from Share Sales by Venture Capital Firms and OthersA theme 62 companies write about · 62 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2019: 2 of 13 companies on the "Worse" side.

20 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 62 companies compared. The sentences above are computed from all 62.
Full recordFilings, disclosures and news, newest first
  1. FY2024MitigatedAnnual report

    「2024年9月30日現在、当社発行済株式総数は6,810,700株(潜在株式を除く。)であり、うちベンチャーキャピタル及びベンチャーキャピタルが組成した投資事業組合等(以下、「VC等」という。)が所有する株式数は6.0%を占めております。」

    VC等の保有比率は前回記載の14.6%から6.0%へ低下し、VC等の売却による需給悪化リスクへのエクスポージャーがさらに縮小した。ただし、売却可能性自体は引き続き記載している。
  2. FY2023MitigatedAnnual report

    「2023年9月30日現在、当社発行済株式総数は5,522,200株(潜在株式を除く。)であり、うちベンチャーキャピタル及びベンチャーキャピタルが組成した投資事業組合等(以下、「VC等」という。)が所有する株式数は14.6%を占めております。」

    VC等の保有比率は、FY2022記載の28.5%から14.6%へ低下し、VC等の株式売却による需給悪化リスクのエクスポージャーが縮小した。ただし、売却可能性自体は引き続き開示している。
  3. FY2022MitigatedAnnual report

    「2022年9月30日現在、当社発行済株式総数は5,380,700株(潜在株式を除く。)であり、うちベンチャーキャピタル及びベンチャーキャピタルが組成した投資事業組合等(以下、「VC等」という。)が所有する株式数は28.5%を占めております。」

    VC等の保有比率は、FY2020記載の46.9%から28.5%となっており、売却による需給悪化リスクのエクスポージャーが低下している。
  4. FY2020First statedAnnual report

    「As of the filing date, the total number of shares issued by the company was 4,227,700 shares, excluding potential shares, of which shares held by venture capital firms and investment partnerships organized by venture capital firms and others represented 46.9%.」

    The company disclosed that venture capital firms and others held 46.9%, creating the possibility that post-listing sales could worsen supply and demand and lower the market price.
Moved together

"Joint research with universities and specialized institutions and use of public funding" moved the same way as this thread, in the same document, in 3 of its 4 moves.

333222★123456
  1. ★This thread
  2. 1Joint research with universities and specialized institutions and use of public funding3×
  3. 2Strengthening the financial position through equity financing, active pharmaceutical ingredient supply and joint development3×
  4. 3Raising funds through a stock listing and private placement3×
  5. 4Monetizing international sales expansion and active pharmaceutical ingredient supply2×
  6. 5Achieving proof of concept through a subsequent trial for vocal fold scarring2×
  7. 6Monetization through upfront payments, milestones and royalties2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Kringle Pharma yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Share price declines resulting from venture capital and other investors selling shares | Kringle Pharma,Inc. (4884) | Komori